504 related articles for article (PubMed ID: 19232036)
21. No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Blatt JA; Poole JE; Johnson GW; Callans DJ; Raitt MH; Reddy RK; Marchlinski FE; Yee R; Guarnieri T; Talajic M; Wilber DJ; Anderson J; Chung K; Wong WS; Mark DB; Lee KL; Bardy GH;
J Am Coll Cardiol; 2008 Aug; 52(7):551-6. PubMed ID: 18687249
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of the implantable cardioverter defibrillator: a preliminary analysis.
O'Brien BJ; Buxton MJ; Rushby JA
Br Heart J; 1992 Aug; 68(2):241-5. PubMed ID: 1389748
[TBL] [Abstract][Full Text] [Related]
25. CHronic use of Amiodarone aGAinSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy Study: rationale and design of a randomized clinical trial.
Martinelli M; Rassi A; Marin-Neto JA; de Paola AA; Berwanger O; Scanavacca MI; Kalil R; de Siqueira SF
Am Heart J; 2013 Dec; 166(6):976-982.e4. PubMed ID: 24268211
[TBL] [Abstract][Full Text] [Related]
26. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Bardy GH; Lee KL; Mark DB; Poole JE; Packer DL; Boineau R; Domanski M; Troutman C; Anderson J; Johnson G; McNulty SE; Clapp-Channing N; Davidson-Ray LD; Fraulo ES; Fishbein DP; Luceri RM; Ip JH;
N Engl J Med; 2005 Jan; 352(3):225-37. PubMed ID: 15659722
[TBL] [Abstract][Full Text] [Related]
27. Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study.
Olshansky B; Poole JE; Johnson G; Anderson J; Hellkamp AS; Packer D; Mark DB; Lee KL; Bardy GH;
J Am Coll Cardiol; 2008 Apr; 51(13):1277-82. PubMed ID: 18371559
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of implantable cardioverter-defibrillators.
Sanders GD; Hlatky MA; Owens DK
N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
[TBL] [Abstract][Full Text] [Related]
29. Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis.
Hallstrom AP; Wyse DG; McAnulty J; ;
J Interv Card Electrophysiol; 2008 Dec; 23(3):159-66. PubMed ID: 18810620
[TBL] [Abstract][Full Text] [Related]
30. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
Hilleman DE; Bauman AL
Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745
[TBL] [Abstract][Full Text] [Related]
31. Quality of life in patients with implantable cardioverter-defibrillator: systematic review of randomized controlled trials.
da Silva KR; Costa R; Rodrigues CG; Schasechter A; Nobre MC; Passman R; Mark DB
Eur J Cardiovasc Nurs; 2018 Mar; 17(3):196-206. PubMed ID: 29067836
[TBL] [Abstract][Full Text] [Related]
32. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society.
Silka MJ; Kron J; Dunnigan A; Dick M
Circulation; 1993 Mar; 87(3):800-7. PubMed ID: 8443901
[TBL] [Abstract][Full Text] [Related]
33. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death.
Claro JC; Candia R; Rada G; Baraona F; Larrondo F; Letelier LM
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD008093. PubMed ID: 26646017
[TBL] [Abstract][Full Text] [Related]
34. Letter regarding article by Bokhari et al, "Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS)".
Boriani G; Biffi M; Martignani C
Circulation; 2005 Jan; 111(3):e26; author reply e26. PubMed ID: 15668348
[No Abstract] [Full Text] [Related]
35. The cost effectiveness of implantable cardioverter defibrillators: a systematic review of economic evaluations.
Gialama F; Prezerakos P; Maniadakis N
Appl Health Econ Health Policy; 2014 Feb; 12(1):41-9. PubMed ID: 24243517
[TBL] [Abstract][Full Text] [Related]
36. Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete?
Cooley R; Akhtar M; Sra J
Curr Cardiol Rep; 1999 Nov; 1(4):268-73. PubMed ID: 10980853
[TBL] [Abstract][Full Text] [Related]
37. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator.
Prystowsky EN
Rev Cardiovasc Med; 2003; 4 Suppl 2():S47-54. PubMed ID: 12776013
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of implantable cardioverter defibrillator therapy versus drug therapy for patients at high risk of sudden cardiac death.
Spath MA; O'Brien BJ
Pharmacoeconomics; 2002; 20(11):727-38. PubMed ID: 12201792
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Children with Cardiac Conditions Associated with Risk for Sudden Cardiac Death.
Haag MB; Hersh AR; Toffey DE; Sargent JA; Stecker EC; Heitner SB; Caughey AB; Balaji S
Pediatr Cardiol; 2020 Oct; 41(7):1484-1491. PubMed ID: 32623612
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
